Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Differential effects of decoy receptor- and antibody-mediated tumour necrosis factor blockage on FoxP3 expression in responsive arthritis patients

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. ERG protein expression at diagnosis is associated with increased risk of disease progression during active surveillance

    Research output: Contribution to journalConference abstract in journalResearch

  2. Differences of macrophage and T cell infiltration in colorectal liver metastases

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  3. Frequency of centromere 17 polysomy in a Danish HER2 2+ borderline breast cancer population

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  4. Is nerve-sparing radical prostatectomy associated with increased risk of iatrogenic positive surgical margins in localised prostate cancer

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  1. Identification of the novel HLA allele, HLA-C*07:780, identified in a Danish woman

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Weight-bearing MRI of the Lumbar Spine: Spinal Stenosis and Spondylolisthesis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Weight-bearing MRI of the Lumbar Spine: Technical Aspects

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Our aim was to clarify if anti-tumour necrosis factor (TNF) drugs have effect on expression of three splice forms of FoxP3 mRNA in blood CD4+ T cells from rheumatoid arthritis (RA) patients compared with healthy controls. Forty-five rheumatoid arthritis patients treated with anti-TNF therapy were investigated in a 12-week prospective cohort study. FoxP3 isoforms, CD25 and CTLA-4 mRNA in blood CD4+ T cells were measured with quantitative real-time PCR. Patients benefitting from the treatment, based on changes in DAS28 scores, revealed a significant decrease in expression of full-length FoxP3 following 12 weeks treatment with TNF receptor 2 fusion protein (Etanercept), but not following treatment with anti-TNF antibodies (Adalimumab or Infliximab). A partial normalization of the CTLA-4/FoxP3fl ratio and a correlation between clinical improvement and change in FoxP3 mRNA expression were also seen in Etanercept responders. These changes were not observed in responsive patients treated with the antibody therapies. Our data suggest that TNF decoy receptor and anti-TNF antibodies differ in their effect on FoxP3 expression in responsive patients. As Etanercept binds both TNF-α and Lymphotoxin-α (LT-α), whereas the antibodies only target TNF-α, LT-α may regulate FoxP3 expression in a subset of RA patients. Our findings support the view that anti-TNF treatment is mainly symptomatic.
Original languageEnglish
Book seriesAPMIS Supplementum
Volume121
Issue number4
Pages (from-to)337-47
Number of pages11
ISSN0903-465X
DOIs
Publication statusPublished - Apr 2013

    Research areas

  • Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Arthritis, Rheumatoid, Cohort Studies, Female, Forkhead Transcription Factors, Humans, Immunoglobulin G, Male, Middle Aged, Prospective Studies, RNA, Messenger, Receptors, Tumor Necrosis Factor, Tumor Necrosis Factor-alpha

ID: 39039571